Antitrust litigation filed against Dr Reddy’s Laboratories, other generic pharma companies in US, Health Information, ET HealthWorld

New Delhi: Dr Reddy’s Laboratories Ltd on Tuesday stated it’s amongst a number of generic pharmaceutical companies, together with Celgene and Bristol Myers Squibb, against which an antitrust litigation has been filed in the United States. In a regulatory submitting, the corporate stated a grievance used to be filed on November 18, 2022, in the District of New Jersey, USA, and it along side other generic pharmaceutical companies were named as defendants.

“The grievance, which purports to be on behalf of a category of oblique clients, asserts claims beneath federal and state antitrust rules and other state rules alleging that the defendants improperly restrained festival and maintained a shared monopoly in the sale of name and generic Revlimid thru their respective settlements of patent litigation,” Dr Reddy’s Laboratories stated.
Revlimid is a prescription medication, used to regard adults with a couple of myeloma (MM) in mixture with dexamethasone, or as repairs remedy after one of those stem cellular transplant that makes use of a person’s personal stem cells.

The corporate stated the grievance “alleges that the challenged agreements improperly behind schedule generic access fully till 2022 after which improperly restricted generic festival thru 2026.”

The grievance seeks damages for purported overpayments and equitable reduction, it added.

Dr Reddy’s asserted that “the allegations against it lack advantage and can vigorously protect the litigation”.

Source link

Posted on

Leave a Reply

Your email address will not be published. Required fields are marked *